Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Jun 30;32(6):308–314. doi: 10.1002/clc.20514

The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program

Xiankai Li 1, Yawei Xu 2, Jue Li 1, Dayi Hu 1,2,✉
PMCID: PMC6653262  PMID: 19569062

Abstract

Background

The China Cholesterol Education Program (CCEP) aimed to investigate the baseline characteristics of outpatients with coronary heart disease (CHD) according to gender, especially lipid levels, statin intervention, and rates of achieving their goal low‐density lipoprotein cholesterol (LDL‐C) level.

Methods

A total of 4778 CHD outpatients were enrolled from 52 centers in 6 Chinese cities from January 2006 to January 2007.

Results

Female outpatients were significantly older than male outpatients (66±10 vs 63±11 years, P <0.001). Male outpatients were more likely to smoke than female outpatients (P<0.001). Female outpatients had a higher prevalence of hypertension, diabetes mellitus, LDL‐C level, and total cholesterol level (all P values <0.001). About 82% of the participants received statin therapy. The LDL‐C levels were 3.06±1.08 mmol/L and 2.89±0.97 mmol/L in outpatients at high risk and very high risk respectively (P<0.001). Though there were higher rates of statin intervention, only 36.2% of the high risk outpatients got to the target LDL‐C level (<2.6 mmol/L); 10.9% of the very high risk outpatients achieved the optimal LDL‐C level (<1.82 mmol/L) suggested by National Cholesterol Education Program Adult Treatment Panel III. The rate of achieving target was only 42.2%, even when LDL‐C <2.6 mmol/L was the target level for patients at very high risk. Only 19.4% of the outpatients at very high risk achieved the target (LDL‐C <2.08 mmol/L) suggested by the updated Chinese guideline for CHD.

Conclusion

Although the outpatients received a higher rate of statin therapy, the rates of achieving the target were lower. There is still a significant gap between the guidelines and clinical practice in statin intervention among these CHD outpatients, particularly for women. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (116.8 KB).

References

  • 1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular disease: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746–2753. [DOI] [PubMed] [Google Scholar]
  • 2. Wu Z, Yao C, Zhao D, et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China—results of Sino‐MONICA project. Eur J Cardiovasc Prev Rehabil 2004; 11: 275–283. [DOI] [PubMed] [Google Scholar]
  • 3. 3. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi‐Provincial Cohort Study. JAMA 2004; 291: 2591–2599. [DOI] [PubMed] [Google Scholar]
  • 4. Wang W, Zhao D, Liu J, et al. Serum total cholesterol and 10‐year cardiovascular risk in a Chinese cohort aged 35–64 years. [in Chinese] Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 169–173. [PubMed] [Google Scholar]
  • 5. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847. [DOI] [PubMed] [Google Scholar]
  • 6.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 7–22.12114036 [Google Scholar]
  • 7. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630. [DOI] [PubMed] [Google Scholar]
  • 8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389. [PubMed] [Google Scholar]
  • 9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009. [DOI] [PubMed] [Google Scholar]
  • 10.The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357. [DOI] [PubMed] [Google Scholar]
  • 11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307. [DOI] [PubMed] [Google Scholar]
  • 12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622. [DOI] [PubMed] [Google Scholar]
  • 13. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double‐blind trial. Lancet. 2001; 357: 577–581. [DOI] [PubMed] [Google Scholar]
  • 14. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055–2060. [DOI] [PubMed] [Google Scholar]
  • 15. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid‐lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071–1080. [DOI] [PubMed] [Google Scholar]
  • 16. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435. [DOI] [PubMed] [Google Scholar]
  • 17. O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low‐density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142–2146. [DOI] [PubMed] [Google Scholar]
  • 18. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy‐Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504. [DOI] [PubMed] [Google Scholar]
  • 19. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239. [DOI] [PubMed] [Google Scholar]
  • 20. Hong Ma, Luhua Shen, Runlin Gao, et al. Guideline for the management of patients with chronic stable angina pectoris. [in Chinese] Chin J Cardiol 2007; 35(3): 195–206. [Google Scholar]
  • 21. Writing committee to the guideline dyslipidemia in Chinese adult. The guideline for the treatment of dyslipidemia in Chinese adult [in Chinese]. Chin J Cardiol 2007; 35: 390–420. [Google Scholar]
  • 22. Wenger NK. Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 2003; 46: 199–229. [DOI] [PubMed] [Google Scholar]
  • 23. Eaker ED, Packard B, Thom TJ. Epidemiology and risk factors for coronary heart disease in women. Cardiovasc Clin 1989; 19: 129–145. [PubMed] [Google Scholar]
  • 24. Cooke CE, Hammerash WJ Jr. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland‐based health maintenance organization. Clin Ther 2006; 28: 591–599. [DOI] [PubMed] [Google Scholar]
  • 25. Khaw KT. Epidemiology of coronary heart disease in women. Heart 2006; 92(suppl 3): 1112–1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women: an update. Curr Opin Cardiol 2006; 21: 602–607. [DOI] [PubMed] [Google Scholar]
  • 27. Nagashima H, Kasanuki H. The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low‐density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. J Atheroscler Thromb 2005; 12: 338–342. [DOI] [PubMed] [Google Scholar]
  • 28. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238–1244. [DOI] [PubMed] [Google Scholar]
  • 30. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8: 155–166. [DOI] [PubMed] [Google Scholar]
  • 31. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 91: 1314–1319. [DOI] [PubMed] [Google Scholar]
  • 32. Chan AW, Bhatt DL, Chew DP et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750–1756. [DOI] [PubMed] [Google Scholar]
  • 33. Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol 2004; 58: 528–535. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES